SRJR LIFESCIENCES LLP has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SRJR Lifesciences LLP, the promoter of Bafna Pharmaceuticals, has submitted a routine annual declaration to BSE and NSE under SEBI's Takeover Regulations. The promoter confirmed that it has not created any encumbrance (pledge, lien, or charge) on the shares it holds in Bafna Pharmaceuticals during the financial year ended March 31, 2025. This is a compliance filing required every year from promoters to assure exchanges that no hidden encumbrance has been placed on promoter-held shares. The declaration was signed by Upendar Mekala Reddy, Designated Partner of SRJR Lifesciences LLP.
This is a neutral, routine compliance filing with no material impact on shareholders or the stock price. It simply reassures the market that the promoter has not pledged or encumbered any of its shares, which is mildly positive as it signals no immediate financial stress at the promoter level.